Literature DB >> 3296644

Gaucher disease--Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment.

A Erikson.   

Abstract

This investigation was undertaken to study the clinical manifestations, development and course of the Norrbottnian type of Gaucher disease--a type III variant--with emphasis on central nervous system symptomatology and function, to correlate clinical signs with laboratory, neuropathological and biochemical findings, to evaluate effects of splenectomy on the course and severity of the disease and to investigate the effect of bone marrow transplantation. Clinical methods applied were neuropaediatric follow-up examinations, psychometric tests and motor age tests. Conventional neurophysiological, haematological and clinico-chemical methods were used. The investigation comprised 22 patients, 10 girls and 12 boys, in all of whom the clinical diagnosis was confirmed by enzymatic tests. The median age at diagnosis was 1.9 years. The clinical pattern at diagnosis was usually that of an alert child with normal intelligence, short stature, splenomegaly, a tendency to bleeding and ocular manifestations. The course was slowly progressive but varied considerably between patients. The median age at death in a representative group of patients was 11.8 years. Early motor development was delayed in the lower limbs but normal in the upper. Eight patients later developed ataxia and six patients signs of mild spastic paraparesis which usually appeared many years after splenectomy. IQ tended to decrease with age. Early splenectomy resulted in lower IQ scores than late splenectomy. With progression of the disease, EEG abnormalities became increasingly frequent, more markedly among splenectomized patients. Thirteen patients had abducens nerve weakness and ten had age dependent abnormalities of horizontal gaze. Retinal infiltrates were characteristic, mainly among splenectomized patients. At, autopsy, Gaucher cell accumulations were found in the adventitia of brain venules, most frequently in cerebral and cerebellar subcortical white matter. Intraneuronal storage of glucosylceramide was observed. The highest concentrations of glucosylceramide were in the cerebellum and cerebral subcortical white matter of splenectomized patients. The fatty acid composition of glucosylceramide from these regions indicated an extracerebral origin in splenectomized patients, but mainly cerebral in nonsplenectomized. Psychosine was found, the highest concentrations in cerebral and cerebellar cortex. Bone marrow transplantation was performed in a nine-year old girl. A three-year follow-up showed very encouraging results both biochemically and clinically. The Norrbottnian type of Gaucher disease is a well defined nosological entity with a characteristic course and clinical manifestations.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1986        PMID: 3296644

Source DB:  PubMed          Journal:  Acta Paediatr Scand Suppl        ISSN: 0300-8843


  19 in total

Review 1.  Remaining problems in the management of patients with Gaucher disease.

Authors:  A Erikson
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

Review 2.  Management of neuronopathic Gaucher disease: a European consensus.

Authors:  A Vellodi; B Bembi; T B de Villemeur; T Collin-Histed; A Erikson; E Mengel; A Rolfs; A Tylki-Szymanska
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

Review 3.  Enzyme-replacement therapy: problems and prospects.

Authors:  B Rademaker; J Raber
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

4.  Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.

Authors:  J J MacKenzie; D Amato; J T Clarke
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

5.  Radiographic findings in type 3b Gaucher disease.

Authors:  S C Hill; B M Damaska; M Tsokos; C Kreps; R O Brady; N W Barton
Journal:  Pediatr Radiol       Date:  1996-12

6.  Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease.

Authors:  V Koprivica; D L Stone; J K Park; M Callahan; A Frisch; I J Cohen; N Tayebi; E Sidransky
Journal:  Am J Hum Genet       Date:  2000-05-04       Impact factor: 11.025

7.  Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings.

Authors:  N Conradi; M Kyllerman; J E Månsson; A K Percy; L Svennerholm
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 8.  Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.

Authors:  E H Davies; A Erikson; T Collin-Histed; E Mengel; A Tylki-Szymanska; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2007-11-12       Impact factor: 4.982

9.  Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry.

Authors:  Anna Tylki-Szymańska; Ashok Vellodi; Amal El-Beshlawy; J Alexander Cole; Edwin Kolodny
Journal:  J Inherit Metab Dis       Date:  2010-01-19       Impact factor: 4.982

10.  Management of neuronopathic Gaucher disease: revised recommendations.

Authors:  A Vellodi; A Tylki-Szymanska; E H Davies; E Kolodny; B Bembi; T Collin-Histed; E Mengel; A Erikson; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-08-05       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.